Under the Paperwork Reduction Act of 1995, no persons are required to respond to a

INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10675721		
Filing Date		2003-09-30		
First Named Inventor	Levin	e et al.		
Art Unit		2191		
Examiner Name Naha		r, Qamrun		
Attorney Docket Number		AUS920030483US1		

	Remove					
Examiner Cite No				ind lode1 Issue Date Name of Patentee or Applicat of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1 5966538 1999-10-12		Granston et al.				
2 5040616 1999-08-17 3 6189142 B1 2001-02-13		5940618		1999-08-17	Blandy et al.	
		Johnston et al.				
	4 5768500 1998-06-16		Agrawal et al.			
	5	6026235		2000-02-15	Shaughnessy	
6 5950003		5950003		1999-09-07	Kaneshiro et al.	
	7	6594820	B1	2003-07-15	Ungar	
If you wis	h to a	dd additional U.S. Pater			ease click the Add button.	Add
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10675721		
Filing Date		2003-09-30		
First Named Inventor Levin		e et al.		
Art Unit		2191		
Examiner Name	Naha	r, Qamrun		
Attorney Docket Numb	er	AUS920030483US1		

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publica Date	ition	of cited Document		Releva	int Passa; s Appear	ges or Relev	/ant
	1	20020073406	A1	2002-0	6-13	Gove					
	2	20030066055	A1	2003-0	4-03	Spivey					
	3	20030131343	A1	2002-0	7-10	French et al.					
	4	20040268316	A1	2004-1	2-30	Fisher et al.					
If you wis	h to a	dd additional U.S. Publi:						d button	$\overline{}$		
				FOREIG	SN PAT	TENT DOCUM	ENTS		Remove		
Examiner Initial*	iminer Cite   Foreign Document   Country   Code*   Date   Pages Columns Lift where Released   Pages Co						evant or Relevant	т			
	1										
If you wis	h to a	dd additional Foreign Pa	atent Do	cument	citation	information pl	lease click the Add	button	Add		
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*								T5			
	1										
If you wis	h to a	d additional non-paten	t literatu	re docu	ment cit	ation informati	ion please click the	Add bu	tton Ac	id	

	Application Number		10675721	
	Filing Date		2003-09-30	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Levin		ne et al.	
(Not for submission under 37 CFR 1.99)	Art Unit		2191	
(	Examiner Name Naha		ır, Qamrun	
	Attorney Docket Numb	er	AUS920030483US1	

EXAMINER SIGNATURE						
Examiner Signature		Date Considered				
	reference considered, whether or not citation is in conforma rmance and not considered. Include copy of this form with r					

See Kind Codes of USPTO Patent Documents at young USPTO.GDY or MPEP 901 (M. <sup>2</sup> Enter office that asseed the document, by the two-letter code (WIPO Standard ST 3). <sup>2</sup> For alguments gleant documents, the advisable of the year of the origin of the Empired must precise the sent number of the patent document. Empire languages translations an advisable.

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10675721		
Filing Date		2003-09-30		
First Named Inventor	Levin	e et al.		
Art Unit		2191		
Examiner Name	Naha	r, Qamrun		
Attorney Docket Number		AUS920030483US1		

#### CERTIFICATION STATEMENT

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(eV1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no tem of Information contained in the information disclosure statement was known to [2] any individual designated in 37 CFR 1.58(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.59(c) more than three months prior to the filing of the information disclosure

See attached certification statement.

Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

□ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gerald H. Glanzman/	Date (YYYY-MM-DD)	2006-10-02			
Name/Print	Geraid H. Glanzman	Registration Number	25035			

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is foll field and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C.12 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Tradenant Afford, U.S. Department of Commence, P. 0. Bot 1450, Alexandria, V.3.251.1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.3.231.1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that. (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kolfice is to process another examine your submission relation to a patient application or patient. If you do not furnish the requested process another examine your submission relation to the patient application or patient. If you do not furnish the requested the process another examines your submission, which may visually intermediate or for extension or about those when the basic high process another examines your submission, which may visually intermediate or for extension or a submission of the basic high process another examines your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pusuant to 5 U.S.C. 552a(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designe, cuting an inspection of records concluded by GSAs a part of that apency's responsibility to recommend improvements in records management practices and programs, under suthority of 4d U.S.C. 2004 and 2006. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 122(b) or issuance of a patent pursuant to 35 U.S. C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record via set float in an application which became abandomed or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issuand patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.